Literature DB >> 7544208

Shared care for benign prostatic hyperplasia: a feasibility study.

S B Morris1, C Pogson, R J Shearer.   

Abstract

OBJECTIVE: To determine the proportion of patients with symptoms of urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) who could be managed in the community after assessment in a shared-care clinic (managed by nursing staff, supervised by a consultant) to which they had direct access. PATIENTS AND METHODS: A total of 127 men were referred to one consultant urologist in a 9-month period for assessment of possible urinary outflow obstruction. All were investigated using urine analysis, serum prostate-specific antigen level, urea and electrolytes, plain abdominal X-ray, renal ultrasonography and urinary flow rate. Additional investigations were undertaken as required. The proportion of men who could have been investigated in a shared-care clinic and then managed in the community was determined.
RESULTS: Of 127 men, 88 (69%) were found to have uncomplicated outflow obstruction secondary to BPH; of these 49 (38%) could have been managed in the community after assessment in the shared-care clinic and a further 27 (21%) could have been managed in the community after additional investigation by a specialist. Twelve men (9%) were found to have uncomplicated outflow obstruction and chose to undergo transurethral resection of the prostate.
CONCLUSION: Many men with uncomplicated outflow obstruction could be assessed in a shared-care clinic and then managed in the community. A shared-care protocol for the management of these men has now been introduced in this unit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544208     DOI: 10.1111/j.1464-410x.1995.tb07836.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  1 in total

1.  The cost effectiveness of a nurse-led shared-care prostate assessment clinic.

Authors:  P Dasgupta; L Drudge-Coates; K Smith; C M Booth
Journal:  Ann R Coll Surg Engl       Date:  2002-09       Impact factor: 1.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.